Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma

Cancer

Volumn 63, Issue 1, 1989, Pages 37-45

  Hortobagyi, G N ^a   Frye, D ^a   Buzdar, A U ^a   Ewer, M S ^a   Fraschini, G ^a   Hug, V ^a   Ames, F ^b   Montague, E ^a   Carrasco, C H ^a   Mackay, B ^a   Benjamin, R S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; TAMOXIFEN;

BREAST CANCER; CARDIOTOXICITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMAN; INFUSIONS, INTRAVENOUS; MIDDLE AGE; MYOCARDIAL DISEASES; PROSPECTIVE STUDIES; RISK FACTORS; STOMATITIS; TAMOXIFEN;

EID: 0024546425     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19890101)63:1<37::AID-CNCR2820630106>3.0.CO;2-Z     Document Type: Article

References (32)

1. A randomized comparative trial of Adriamycin versus methotrexate in combination drug therapy
2. Adriamycin versus methotrexate in five‐drug combination chemotherapy for advanced breast cancer: A randomized trial
3. Risk factors for doxorubicin induced congestive heart failure
4. Studies on Adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity
5. Adriamycin given as a weekly schedule without a loading course: Clinically effective with reduced incidence of cardiotoxicity
6. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule
7. Increased therapeutic index of weekly doxorubicin in the therapy of non‐small cell lung cancer: A prospective, randomized study
8. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion
9. Continuous infusion Adriamycin
10. Long‐term intravenous therapy with peripherally inserted silicone elastomer central venous catheters in patients with malignant diseases
11. Percutaneous insertion of silicone central venous catheters for long‐term intravenous access in cancer patients
12. Radionuclide ejection fraction in doxorubicin cardiotoxicity
13. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin
14. Anthracycline cardiomyopathy monitored by morphologic changes
15. Assessment of response to therapy in advanced breast cancer
16. Nonparametric estimation from incomplete observations
17. A generalized Wilcoxon test for comparing arbitrarily single‐censored samples
18. Combined antiestrogen and cytotoxic therapy for metastatic breast cancer
19. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer
20. Vindesine in the treatment of refractory breast cancer: Improvement in therapeutic index with continuous 5‐day infusion
21. Bleomycin, an antitumor antibiotic
22. Comparison of continuously infused 5‐fluorouracil with bolus injection in the treatment of patients with colorectal adenocarcinoma
23. Preliminary results of a phase II trial of aclacinomycin in acute leukaemia and lymphosarcoma. An oncostatic anthracyclin that is rarely cardiotoxic and induces no alopecia
24. Quelamycin, a new derivative of Adriamycin with several possible therapeutic advantages
25. Synthesis and antitumor activity of 4‐demethoxyadriamycin and 4‐demethoxy‐4′‐epi‐adriamycin
26. American experience with Carminomycin
27. Clinical studies with Rubidazone
28. Initial clinical evaluation of N‐trifluoroacetyladriamycin‐14‐valerate (AD‐32), and Adriamycin analog
29. Menogaril: A new anthracycline agent entering clinical trials
30. Advantage of an Adriamycin combination plus Halotestin after initial cyclophosphamide, methotrex‐ate, 5‐fluorouracil, vincristine, and prednisone (CMFVP) for adjuvant therapy of node positive stage II breast cancer
31. Management of breast cancer patients failing adjuvant chemotherapy with Adriamycin‐containing regimens